A Purified Recombinant Lipopeptide as Adjuvant for Cancer Immunotherapy
Figure 5
CD8+ T cell response and antitumor effect elicited by lipo-Nter in a peptide vaccine. (a) Mice were subcutaneously administered twice at a 1-week interval with RAH and PADRE (30 μg) mixed with IFA. CD8+ T cells were purified from the spleens of the immunized mice. Purified CD8+ T cells were cocultured with/without BM-DCs and stimulated with PBS or 1 μM RAH mixed with/without 200 nM lipo-Nter for 72 h. Proliferation of T lymphocytes was measured by uptake of [3H]thymidine. (b) TC-1 tumor-bearing mice (6 animals/group) received a single injection of PBS or 10 μg of RAH mixed with/without lipo-Nter (10 μg/100 μL). The tumor diameters are shown (cm3).
